Loading
A phase 2 trial of Bevacizumab and Nogapendekin alfa inbakicept in glioma & glioblastoma, run by ImmunityBio, Inc., active and no longer recruiting.
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma is a phase 2 interventional study registered as NCT06061809 by ImmunityBio, Inc., with 34 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2029-12-31. Interventions recorded: Bevacizumab, PD-L1 t-haNK, N-803 and Tumor Treating Fields (TTFields, 200 kHz).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Cytokines & engineered cytokines and the tag pipeline.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Glioma & glioblastoma, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Glioma & glioblastoma, Monoclonal antibodies and the tag pipeline.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/